Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FALMINA vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Bulimia nervosa,Premenstrual dysphoric disorder
Prevention of pregnancy (FDA-approved)
FALMINA (fictitious drug): 500 mg orally every 12 hours.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life 12-15 hours; in severe renal impairment (Cr Cl <30 m L/min) extends to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Hepatic via CYP2D6; active metabolite norfluoxetine; elimination half-life 4-6 days (fluoxetine), 4-16 days (norfluoxetine).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
0.2-0.3 L/kg, reflecting confinement to plasma and interstitial space; minimal tissue penetration.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 75-85% due to moderate first-pass metabolism; IV: 100%.
Oral: ~70% due to first-pass metabolism.
GFR 30-59 m L/min: 500 mg every 24 hours. GFR 15-29 m L/min: 250 mg every 24 hours. GFR <15 m L/min: 125 mg every 24 hours. Hemodialysis: 125 mg post-dialysis.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use with caution; 250 mg every 24 hours.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
5 mg/kg/dose orally every 12 hours; maximum 500 mg/dose.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Initiate at 250 mg orally every 12 hours; titrate to renal function.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome; discontinuation syndrome; hyponatremia; bleeding risk; mania/hypomania; seizures; angle-closure glaucoma; QT prolongation (overdose).
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Concurrent use with MAOIs or within 14 days of MAOI use; concurrent use with pimozide or thioridazine; hypersensitivity to fluoxetine.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid high-sodium foods as they can counteract the diuretic effect. Limit licorice intake (glycyrrhizin) which can worsen hypokalemia. Grapefruit juice may increase absorption; avoid large amounts. Maintain adequate fluid intake unless fluid restriction is advised.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malformations in exposed fetuses based on epidemiological studies, but use is not recommended due to lack of need. Second and third trimesters: associated with increased risk of fetal harm including congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, preterm birth) from continued exposure. Risk of fetal feminization from progestin component in late pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinylestradiol and drospirenone are excreted in breast milk; M/P ratio not determined. Use may reduce milk production and composition. Avoid use in breastfeeding women, especially during early postpartum period, due to potential for decreased milk supply and presence in milk. Alternative contraception recommended.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Falmina is contraindicated in pregnancy; no dose adjustments are applicable because use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data guide dosing in pregnancy as it is not indicated.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
FALMINA is a high-ceiling loop diuretic used for edema and hypertension. Monitor serum potassium and magnesium regularly; risk of hypokalemia and hypomagnesemia. Ototoxicity is dose-dependent and more common with rapid IV administration or concurrent use of other ototoxic drugs. Onset of action: oral 30-60 min, IV 5 min. Duration: oral 6-8 hr, IV 2 hr. Avoid in anuria, hepatic coma, severe electrolyte depletion.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any hearing loss, ringing in ears, or dizziness immediately, especially if on high doses or other ototoxic drugs.,Weigh yourself daily and notify your doctor if you gain more than 2-3 pounds in 24 hours or lose weight too quickly.,Avoid sudden position changes to prevent dizziness; rise slowly from sitting or lying down.,Limit alcohol intake as it may worsen dizziness and low blood pressure.,This drug may increase blood sugar; monitor glucose if diabetic.,Do not take with NSAIDs (e.g., ibuprofen, aspirin) unless approved by your doctor as they may reduce effectiveness and increase kidney risk.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FALMINA vs AFIRMELLE, answered by our medical review team.
FALMINA is a Oral Contraceptive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FALMINA and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FALMINA is: FALMINA (fictitious drug): 500 mg orally every 12 hours.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FALMINA and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FALMINA is classified as Category C. Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malform. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.